Inhibrx Biosciences, Inc. reported a net loss of $33.4 million for the first quarter of 2026, a decrease from a net loss of $43.3 million in the same period of the previous year, reflecting a 23% improvement. The company's total operating expenses also decreased by 28%, from $42.9 million to $30.9 million, primarily due to a significant reduction in research and development costs, which fell from $36.9 million to $25.2 million. This decline was attributed to decreased clinical trial expenses and contract manufacturing costs as the company nears completion of certain trials.
The company’s cash and cash equivalents increased to $161.7 million as of March 31, 2026, up from $124.2 million at the end of 2025. This increase was bolstered by $75 million in gross proceeds from an amended loan agreement with Oxford Finance LLC, which provided additional funding to support ongoing clinical trials and operational activities. Inhibrx's total liabilities rose to $205 million, primarily due to the increased long-term debt, which now stands at $175 million following the loan amendment.
Inhibrx continues to advance its clinical pipeline, which includes ozekibart (INBRX-109) and INBRX-106, both of which are in various stages of clinical trials. The company announced interim data from its Phase 1/2 study of ozekibart in colorectal cancer, showing a 20% overall response rate and a median progression-free survival of 5.5 months. The company plans to meet with the FDA in the second half of 2026 to discuss potential accelerated pathways for regulatory approval for ozekibart in colorectal cancer and Ewing sarcoma.
As of March 31, 2026, Inhibrx had 14.7 million shares of common stock outstanding, reflecting a slight increase from the previous quarter. The company remains classified as a smaller reporting company and an emerging growth company, allowing it to benefit from certain regulatory exemptions. Looking ahead, Inhibrx anticipates continued investment in its research and development efforts, with expectations of increased expenses as it progresses through clinical trials and prepares for potential commercialization of its therapeutic candidates. The company believes its existing cash reserves will be sufficient to fund operations for at least the next 12 months, although it may seek additional capital through equity offerings or strategic partnerships to support its growth initiatives.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing innovative biologic therapies using proprietary protein engineering platforms. Its focus includes oncology and immunotherapy, with pipeline candidates like ozekibart (INBRX-109) targeting cancer cell death pathways and INBRX-106 enhancing T-cell responses. The company aims to address high unmet medical needs through targeted, differentiated biologics for cancer and immune-related diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.